COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
Abstract Laboratory tests for the accurate and rapid identification of SARS-CoV-2 variants can potentially guide the treatment of COVID-19 patients and inform infection control and public health surveillance efforts. Here we present the development and validation of a rapid COVID-19 variant DETECTR®assay incorporating loop-mediated isothermal amplification (LAMP) followed by CRISPR-Cas12 based identification of single nucleotide polymorphism (SNP) mutations in the SARS-CoV-2 spike (S) gene. This assay targets the L452R, E484K/Q/A, and N501Y mutations that are associated with nearly all circulating viral lineages and identifies the two circulating variants of concern, Delta and Omicron. In a comparison of three different Cas12 enzymes, only the newly identified enzyme CasDx1 was able to accurately identify all targeted SNP mutations. An analysis pipeline for CRISPR-based SNP identification from 139 clinical samples yielded an overall SNP concordance of 98% and agreement with SARS-CoV-2 lineage classification of 138/139 compared to viral whole-genome sequencing. We also showed that detection of the single E484A mutation was necessary and sufficient to accurately identify Omicron from other major circulating variants in patient samples. These findings demonstrate the utility of CRISPR-based DETECTR®as a faster and simpler diagnostic than sequencing for SARS-CoV-2 variant identification in clinical and public health laboratories..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 13. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fasching, Clare L. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.11.29.21267041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI033116288 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI033116288 | ||
| 003 | DE-627 | ||
| 005 | 20231205150251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211201s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.11.29.21267041 |2 doi | |
| 035 | |a (DE-627)XBI033116288 | ||
| 035 | |a (biorXiv)10.1101/2021.11.29.21267041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fasching, Clare L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Laboratory tests for the accurate and rapid identification of SARS-CoV-2 variants can potentially guide the treatment of COVID-19 patients and inform infection control and public health surveillance efforts. Here we present the development and validation of a rapid COVID-19 variant DETECTR®assay incorporating loop-mediated isothermal amplification (LAMP) followed by CRISPR-Cas12 based identification of single nucleotide polymorphism (SNP) mutations in the SARS-CoV-2 spike (S) gene. This assay targets the L452R, E484K/Q/A, and N501Y mutations that are associated with nearly all circulating viral lineages and identifies the two circulating variants of concern, Delta and Omicron. In a comparison of three different Cas12 enzymes, only the newly identified enzyme CasDx1 was able to accurately identify all targeted SNP mutations. An analysis pipeline for CRISPR-based SNP identification from 139 clinical samples yielded an overall SNP concordance of 98% and agreement with SARS-CoV-2 lineage classification of 138/139 compared to viral whole-genome sequencing. We also showed that detection of the single E484A mutation was necessary and sufficient to accurately identify Omicron from other major circulating variants in patient samples. These findings demonstrate the utility of CRISPR-based DETECTR®as a faster and simpler diagnostic than sequencing for SARS-CoV-2 variant identification in clinical and public health laboratories. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Servellita, Venice |4 aut | |
| 700 | 1 | |a McKay, Bridget |4 aut | |
| 700 | 1 | |a Nagesh, Vaishnavi |4 aut | |
| 700 | 1 | |a Broughton, James P. |4 aut | |
| 700 | 1 | |a Sotomayor-Gonzalez, Alicia |4 aut | |
| 700 | 1 | |a Wang, Baolin |4 aut | |
| 700 | 1 | |a Brazer, Noah |4 aut | |
| 700 | 1 | |a Reyes, Kevin |4 aut | |
| 700 | 1 | |a Streithorst, Jessica |4 aut | |
| 700 | 1 | |a Deraney, Rachel N. |4 aut | |
| 700 | 1 | |a Stanfield, Emma |4 aut | |
| 700 | 1 | |a Hendriks, Carley G. |4 aut | |
| 700 | 1 | |a Miller, Steve |4 aut | |
| 700 | 1 | |a Ching, Jesus |4 aut | |
| 700 | 1 | |a Chen, Janice S. |4 aut | |
| 700 | 1 | |a Chiu, Charles Y. |0 (orcid)0000-0003-2915-2094 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 13. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:13 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.11.29.21267041 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 13 |c 11 | ||